Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Rydapt

- PMLiVE

NICE set to block post-Velcade use of Revlimid

Watchdog's new draft guidance does not recommend Celgene blood cancer drug

Novartis building

Novartis’ glaucoma combo cleared in Europe

Simbrinza approved to treat eye condition

- PMLiVE

Neupogen will be first biologic on FDA biosimilars pathway

US regulator will review Novartis’  version of Amgen's Neupogen (filgrastim) over the coming months

National Institute for Health and Care Excellence NICE logo

Lilly’s Efient and Sucampo’s Amitiza win NICE backing

Blood clot and constipation drugs recommended for NHS use

- PMLiVE

NICE backs cancer drugs from Astellas and BMS

Recommendations for Xtandi in prostate cancer and earlier use of Yervoy

National Institute for Health and Care Excellence NICE logo

NICE confirms wider statin use

Reduces threshold for risk of heart disease

Novartis building

Novartis’ vaccine sales decline ahead of GSK transfer

Only business not to show growth during second quarter of 2014

Novartis building

Novartis launches Alzheimer’s prevention study

Will test two treatments in people with genetic risk of dementia

- PMLiVE

Novartis buys rights to Google’s ‘smart lens’ technology

Pharma company's eye unit Alcon will focus on uses in diabetes and presbyopia

Biogen Idec building

NICE green light for Biogen’s oral MS drug

Overturns previous negative guidance for Tecfidera

Novartis building

Novartis’ secukinumab tops Enbrel in psoriasis

Data reinforces secukinumab's position among new generation of biologic

France flag

Pharma criticises France’s backing for off-label Avastin use

EFPIA weighs in on proposal to move wet AMD patients to the drug as a cheaper alternative

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links